ARQT
VENTE TOTALE: 37 229 titres (~943 103,35 $ US)
- Insiders
- Curran Terrie, Welgus Howard G., Watanabe Todd
- Total bought
- —
- Total sold
- $943,103
- Last activity
- 2026-08-27
- Last synced
-
2026-09-02 21:34:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-09-01
ARQT presents a compelling earnings catalyst (score 80, confidence 0.75) driven by a 2026 revenue guidance raise and Zoryve's commercial momentum, supported by institutional accumulation from Bamco and Deutsche Bank.
The first sentence of the analysis written for ARQT on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 90.2% | 90.3% | 91.6% | 79.5% | 0.0% | |
| Ebit Margin | -0.8% | -57.1% | -384.7% | -8025.1% | 0.0% | |
| Ebitda Margin | 0.7% | -55.8% | -381.6% | -7991.1% | 0.0% | |
| Operating Profit Margin | -3.3% | -65.3% | -404.5% | -8183.0% | 0.0% | |
| Pretax Profit Margin | -4.0% | -70.9% | -434.6% | -8449.8% | 0.0% | |
| Continuous Operations Profit Margin | -4.3% | -71.3% | -439.8% | -8449.8% | 0.0% | |
| Net Profit Margin | -4.3% | -71.3% | -439.8% | -8449.8% | 0.0% | |
| Bottom Line Profit Margin | -4.3% | -71.3% | -439.8% | -8449.8% | 0.0% | |
| Current Ratio | 3.167 | 4.145 | 7.080 | 11.569 | 12.086 | |
| Quick Ratio | 2.993 | 3.966 | 6.799 | 11.371 | 12.086 | |
| Solvency Ratio | -0.044 | -0.718 | -1.030 | -1.294 | -1.861 | |
| Cash Ratio | 0.330 | 0.881 | 1.894 | 1.419 | 2.940 | |
| Price To Earnings Ratio | -223.385 | -12.009 | -0.854 | -2.615 | -4.974 | |
| Price To Earnings Growth Ratio | 2.516 | 0.173 | 0.026 | -0.073 | -0.511 | |
| Forward Price To Earnings Growth Ratio | 2.516 | 0.173 | 0.026 | -0.073 | -0.511 | |
| Price To Earnings Diluted Ratio | -223.385 | -12.009 | -0.854 | -2.615 | -4.974 | |
| Price To Earnings Diluted Growth Ratio | 2.516 | 0.173 | 0.026 | -0.073 | -0.511 | |
| Price To Book Ratio | 19.500 | 10.695 | 2.525 | 3.886 | 3.442 | |
| Price To Sales Ratio | 9.825 | 8.573 | 3.756 | 220.964 | 0.000 | |
| Price To Free Cash Flow Ratio | -585.466 | -15.004 | -0.905 | -2.899 | -5.835 | |
| Price To Operating Cash Flow Ratio | -656.867 | -15.023 | -0.906 | -3.160 | -5.868 | |
| Debt To Assets Ratio | 0.014 | 0.317 | 0.603 | 0.451 | 0.190 | |
| Debt To Equity Ratio | 0.033 | 0.702 | 2.322 | 0.966 | 0.261 | |
| Debt To Capital Ratio | 0.032 | 0.412 | 0.699 | 0.491 | 0.207 | |
| Long Term Debt To Capital Ratio | 0.027 | 0.405 | 0.695 | 0.486 | 0.196 | |
| Financial Leverage Ratio | 2.285 | 2.215 | 3.850 | 2.144 | 1.371 | |
| Working Capital Turnover Ratio | 1.403 | 0.730 | 0.174 | 0.010 | 0.000 | |
| Operating Cash Flow Ratio | -0.043 | -1.384 | -5.294 | -6.817 | -5.240 | |
| Operating Cash Flow Sales Ratio | -0.015 | -0.571 | -4.145 | -69.917 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.122 | 1.001 | 1.002 | 1.090 | 1.006 | |
| Debt Service Coverage Ratio | 0.100 | -4.059 | -7.759 | -18.819 | -474.811 | |
| Interest Coverage Ratio | -1.012 | -4.726 | -8.115 | -19.271 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -5.625 | 0.000 | 0.000 | 0.000 | -403.296 | |
| Operating Cash Flow Coverage Ratio | -0.898 | -1.014 | -1.200 | -1.272 | -2.252 | |
| Capital Expenditure Coverage Ratio | -8.200 | -784.322 | -577.236 | -11.069 | -175.505 | |
| Dividend Paid And Capex Coverage Ratio | -8.200 | -784.322 | -577.236 | -11.069 | -175.505 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 1,475.094 | -15.728 | -1.501 | -3.271 | -4.885 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 90.2% | ▼-0.0% | ▲19.9% |
| Ebit Margin | -0.8% | ▲56.3% | ▲1692.8% |
| Ebitda Margin | 0.7% | ▲56.4% | ▲1686.2% |
| Operating Profit Margin | -3.2% | ▲62.1% | ▲1728.0% |
| Pretax Profit Margin | -4.0% | ▲66.9% | ▲1787.9% |
| Continuous Operations Profit Margin | -4.3% | ▲67.0% | ▲1788.7% |
| Net Profit Margin | -4.3% | ▲67.0% | ▲1788.7% |
| Bottom Line Profit Margin | -4.3% | ▲67.0% | ▲1788.7% |
| Current Ratio | 3.167 | ▼-0.978 | ▼-4.442 |
| Quick Ratio | 2.993 | ▼-0.973 | ▼-4.450 |
| Solvency Ratio | -0.044 | ▲0.674 | ▲0.945 |
| Cash Ratio | 0.331 | ▼-0.550 | ▼-1.162 |
| Price To Earnings Ratio | -223.385 | ▼-211.376 | ▼-174.617 |
| Price To Earnings Growth Ratio | 2.516 | ▲2.342 | ▲2.090 |
| Forward Price To Earnings Growth Ratio | 2.516 | ▲2.342 | ▲2.090 |
| Price To Earnings Diluted Ratio | -223.385 | ▼-211.376 | ▼-174.617 |
| Price To Earnings Diluted Growth Ratio | 2.516 | ▲2.342 | ▲2.090 |
| Price To Book Ratio | 19.500 | ▲8.805 | ▲11.491 |
| Price To Sales Ratio | 9.825 | ▲1.252 | ▼-38.799 |
| Price To Free Cash Flow Ratio | -585.466 | ▼-570.462 | ▼-463.444 |
| Price To Operating Cash Flow Ratio | -656.867 | ▼-641.844 | ▼-520.502 |
| Debt To Assets Ratio | 0.015 | ▼-0.302 | ▼-0.301 |
| Debt To Equity Ratio | 0.033 | ▼-0.669 | ▼-0.824 |
| Debt To Capital Ratio | 0.032 | ▼-0.380 | ▼-0.336 |
| Long Term Debt To Capital Ratio | 0.027 | ▼-0.378 | ▼-0.335 |
| Financial Leverage Ratio | 2.285 | ▲0.070 | ▼-0.088 |
| Working Capital Turnover Ratio | 1.403 | ▲0.673 | ▲0.939 |
| Operating Cash Flow Ratio | -0.043 | ▲1.341 | ▲3.712 |
| Operating Cash Flow Sales Ratio | -0.015 | ▲0.556 | ▲14.915 |
| Free Cash Flow Operating Cash Flow Ratio | 1.122 | ▲0.121 | ▲0.078 |
| Debt Service Coverage Ratio | 0.100 | ▲4.159 | ▲101.170 |
| Interest Coverage Ratio | -1.012 | ▲3.714 | ▲5.613 |
| Short Term Operating Cash Flow Coverage Ratio | -5.625 | ▼-5.625 | ▲76.159 |
| Operating Cash Flow Coverage Ratio | -0.898 | ▲0.117 | ▲0.429 |
| Capital Expenditure Coverage Ratio | -8.200 | ▲776.122 | ▲303.066 |
| Dividend Paid And Capex Coverage Ratio | -8.200 | ▲776.122 | ▲303.066 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 1475.094 | ▲1490.823 | ▲1185.152 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.69B | $1.68B | $223.9M | $814.5M | $1.02B | |
| Enterprise value | $3.66B | $1.72B | $341.4M | $963.4M | $1.00B | |
| EV / Sales | 9.73x | 8.77x | 5.73x | 261.36x | 0.00x | |
| EV / Op. cash flow | -650.35x | -15.37x | -1.38x | -3.74x | -5.75x | |
| EV / Free cash flow | -579.66x | -15.35x | -1.38x | -3.43x | -5.72x | |
| EV / EBITDA | 1475.09x | -15.73x | -1.50x | -3.27x | -4.88x | |
| Net debt / EBITDA | -14.78x | -0.36x | -0.52x | -0.51x | 0.10x | |
| Current ratio | 3.17x | 4.14x | 7.08x | 11.57x | 12.09x | |
| Income quality | 0.35x | 0.80x | 0.94x | 0.83x | 0.85x | |
| Graham net-net | $1 | $1 | $1 | $3 | $6 | |
| Tax burden | 107.8% | 100.5% | 101.2% | 100.0% | 100.0% | |
| Interest burden | 518.5% | 124.2% | 113.0% | 105.3% | 100.0% | |
| Working capital | $281.4M | $254.8M | $283.8M | $399.6M | $369.4M | |
| Invested capital | $301.7M | $267.3M | $294.1M | $411.4M | $374.7M | |
| Return on assets | -3.7% | -40.1% | -76.8% | -69.3% | -50.6% | |
| Operating ROA | -3.1% | -37.2% | -61.0% | -70.4% | -58.5% | |
| Return on tangible assets | -3.9% | -41.3% | -78.3% | -70.5% | -50.6% | |
| Return on equity | -8.5% | -88.9% | -295.6% | -148.6% | -69.3% | |
| Return on invested capital | -4.0% | -47.8% | -81.6% | -73.2% | -55.0% | |
| Return on capital employed | -4.0% | -47.9% | -81.8% | -73.3% | -55.1% | |
| Earnings yield | -0.4% | -8.3% | -117.1% | -38.2% | -20.1% | |
| Free cash flow yield | -0.2% | -6.7% | -110.6% | -34.5% | -17.1% | |
| Capex / Op. cash flow | -12.2% | -0.1% | -0.2% | -9.0% | -0.6% | |
| Capex / Depreciation | 14.7% | 5.5% | 28.1% | 2492.8% | 219.2% | |
| Capex / Sales | 0.2% | 0.1% | 0.7% | 631.7% | 0.0% | |
| SG&A / Sales | 73.0% | 116.7% | 310.6% | 3313.2% | 0.0% | |
| R&D / Sales | 20.5% | 38.9% | 185.5% | 4949.4% | 0.0% | |
| Stock comp / Sales | 10.7% | 21.2% | 65.1% | 886.7% | 0.0% | |
| Intangibles / Total assets | 3.4% | 2.7% | 1.9% | 1.6% | 0.0% | |
| Days sales outstanding | 142d | 136d | 158d | 838d | 0d | |
| Days payables outstanding | 125d | 271d | 878d | 4273d | 3517d | |
| Operating cycle | 367d | 413d | 1119d | 4475d | 0d | |
| Cash conversion cycle | 242d | 142d | 242d | 202d | -3517d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+119.3%EV / Sales ▲+10.9%EV / EBITDA ▲+9478.7%EV / Op. cash flow ▼-634.980Earnings yield ▲+0.079
Profitability
Return on equity ▲+0.804Return on assets ▲+0.364Return on invested capital ▲+0.438Return on capital employed ▲+0.439Operating ROA ▲+0.341Income quality ▼-0.452Tax burden ▲+0.074
Efficiency
Days sales outstanding ▲+6.232Days payables outstanding ▼-146.731Operating cycle ▼-45.815Cash conversion cycle ▲+100.916Capex / Sales ▲+0.001R&D / Sales ▼-0.184
Balance-sheet strength
Current ratio ▼-0.978Net debt / EBITDA ▼-14.417Working capital ▲+26587000.000Invested capital ▲+34436000.000Intangibles / Total assets ▲+0.007
Change over 5 years
Valuation
Market cap ▲+260.6%EV / Sales n/aEV / EBITDA ▲+30298.7%EV / Op. cash flow ▼-644.602Earnings yield ▲+0.197
Profitability
Return on equity ▲+0.608Return on assets ▲+0.468Return on invested capital ▲+0.510Return on capital employed ▲+0.511Operating ROA ▲+0.553Income quality ▼-0.498Tax burden ▲+0.078
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-3392.876Operating cycle n/aCash conversion cycle ▲+3759.937Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-8.919Net debt / EBITDA ▼-14.874Working capital ▼-88053000.000Invested capital ▼-73032000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-11 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-04-17 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-06-15 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-28 Here''s Why You Should Add ARQT Stock to Your Portfolio Now Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
- 2026-08-27 Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
- 2026-08-27 Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT Bamco Inc. NY acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,253,120 shares of the company''s stock, valued at approximately $32,857,000. Bamco Inc. NY owned
- 2026-08-26 5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
- 2026-08-24 382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AG Deutsche Bank AG bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 382,682 shares of the company''s stock, valued at approximately $10,034,000. Deutsche Bank AG owned approximately 0.31% of Arcutis
- 2026-08-07 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis'' common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis'' common stock to 24 newly hired employees.
- 2026-08-06 Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability Watanabe''s sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.
- 2026-08-05 Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
- 2026-08-05 Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share a year ago.
- 2026-08-05 Arcutis Biotherapeutics Q2 Earnings Call Highlights Arcutis Biotherapeutics NASDAQ: ARQT reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to rise across approved dermatology indications.